Vivus Escapes Shareholder Suit Over Obesity Drug Safety

Law360, New York (September 28, 2012, 3:43 PM EDT) -- A California federal judge on Thursday dismissed a putative class action accusing drugmaker Vivus Inc. of lying to investors about the risks of its recently approved obesity treatment Qsymia, ruling the company had made adequate disclosures about the drug.

U.S. District Judge Phyllis J. Hamilton said that Mountain View, Calif.-based Vivus had not hidden the risks of Qsymia in an attempt to mislead investors about the chances of U.S. Food and Drug Administration approval for the drug, having consistently made available information about the nature and...
To view the full article, register now.